Qi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qi Wang has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Quli Fan
State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM) Nanjing University of Posts & Telecommunications Nanjing China
15 shared publications Wei Huang
State Key Laboratory for Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing 210023, China; Frontiers Science Center for Flexible Electronics (FSCFE), MIIT Key Laboratory of Flexible Electronics (KLoFE), Northwestern Polytechnical University, Xi'an 710072, China
8 shared publicationsJiawei Liu
State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM) Nanjing University of Posts & Telecommunications Nanjing China
7 shared publications- Tangxin Xiao
School of Petrochemical Engineering Changzhou University Changzhou China
7 shared publications - Feng Lu
Key Laboratory for Organic Electronics and Information Displays, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China
6 shared publications Lu Tian
Key Laboratory for Organic Electronics and Information Displays & Jiangsu Key Laboratory for Biosensors
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Chemistry – A European Journal
- p. e71891
A Hypoxia‐Activated Diketopyrrolopyrrole‐Based Single‐Molecule Prodrug for Combined Chemotherapeutic and Type‐I Photodynamic/Photothermal Trimodal Cancer Therapy
Hypoxia, as a unique tumor microenvironment, offers an opportunity for the development of activatable therapeutic agents. However, most current activatable agents are confined to monotherapy, limiting their overall efficacy. We herein report a novel single‐molecule prodrug for hypoxia‐activated trimodal cancer therapy. A diketopyrrolopyrrole‐based molecule ( AMO ) was first synthesized, demonstrating efficient type‐I photodynamic (PDT) and photothermal (PTT) activities. To integrate chemotherapy, a hypoxia‐cleavable azo linker was introduced to conjugate a cytotoxic drug, nitrogen mustard, yielding the prodrug AIO . Under normoxic conditions, the AIO exhibited attenuated phototherapeutic effects, minimizing off‐target toxicity. In contrast, the hypoxic tumor environment triggered azo cleavage, releasing the chemotherapeutic agent while simultaneously restoring type‐I PDT and PTT functionalities. This work provides an activatable trimodal combination therapeutic strategy with promising translational potential for precise cancer treatment.
- 9 November 2026
- Published by Wiley in Chemistry – A European Journal
- p. e71891
Open AccessA Hypoxia‐Activated Diketopyrrolopyrrole‐Based Single‐Molecule Prodrug for Combined Chemotherapeutic and Type‐I Photodynamic/Photothermal Trimodal Cancer Therapy
Hypoxia, as a unique tumor microenvironment, offers an opportunity for the development of activatable therapeutic agents. However, most current activatable agents are confined to monotherapy, limiting their overall efficacy. We herein report a novel single‐molecule prodrug for hypoxia‐activated trimodal cancer therapy. A diketopyrrolopyrrole‐based molecule ( AMO ) was first synthesized, demonstrating efficient type‐I photodynamic (PDT) and photothermal (PTT) activities. To integrate chemotherapy, a hypoxia‐cleavable azo linker was introduced to conjugate a cytotoxic drug, nitrogen mustard, yielding the prodrug AIO . Under normoxic conditions, the AIO exhibited attenuated phototherapeutic effects, minimizing off‐target toxicity. In contrast, the hypoxic tumor environment triggered azo cleavage, releasing the chemotherapeutic agent while simultaneously restoring type‐I PDT and PTT functionalities. This work provides an activatable trimodal combination therapeutic strategy with promising translational potential for precise cancer treatment.
- 19 January 2026
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 42 (4) , 3604-3611
Pillar[5]arene-Mediated Assembly of Amphiphiles for Enhanced Light Harvesting and Photocatalysis
In nature, photosynthetic organisms such as cyanobacteria efficiently capture, transfer, and utilize solar energy in aqueous environments. However, replicating these processes in artificial supramolecular systems to achieve effective light harvesting and photocatalysis in water remains highly challenging. Here, we report a supramolecular light-harvesting system (LHS) constructed from a water-soluble dicarboxylate pillar[5]arene (H2), a triphenylacrylonitrile derivative (TPAN), and the acceptor dye 4,7-di(2-thienyl)benzo[2,1,3]thiadiazole (DBT). Structural optimization of the host enhanced the emission of the H2-TPAN supra-amphiphile by 2.5-fold compared with its fully carboxylated analogue (H1). The resulting ternary LHS exhibited excellent performance, enabling efficient generation of both singlet oxygen (1O2) and superoxide anion radical (O2•-). These reactive oxygen species (ROS) synergistically promoted metal-free oxidative amidation in water, affording methacetin and related derivatives in yields of up to 95%. This work demonstrates how rational supramolecular design can integrate fluorescence amplification, light harvesting, and dual-ROS generation into a single platform for efficient photocatalysis in aqueous media.
- 19 January 2026
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 42 (4) , 3604-3611
Pillar[5]arene-Mediated Assembly of Amphiphiles for Enhanced Light Harvesting and Photocatalysis
In nature, photosynthetic organisms such as cyanobacteria efficiently capture, transfer, and utilize solar energy in aqueous environments. However, replicating these processes in artificial supramolecular systems to achieve effective light harvesting and photocatalysis in water remains highly challenging. Here, we report a supramolecular light-harvesting system (LHS) constructed from a water-soluble dicarboxylate pillar[5]arene (H2), a triphenylacrylonitrile derivative (TPAN), and the acceptor dye 4,7-di(2-thienyl)benzo[2,1,3]thiadiazole (DBT). Structural optimization of the host enhanced the emission of the H2-TPAN supra-amphiphile by 2.5-fold compared with its fully carboxylated analogue (H1). The resulting ternary LHS exhibited excellent performance, enabling efficient generation of both singlet oxygen (1O2) and superoxide anion radical (O2•-). These reactive oxygen species (ROS) synergistically promoted metal-free oxidative amidation in water, affording methacetin and related derivatives in yields of up to 95%. This work demonstrates how rational supramolecular design can integrate fluorescence amplification, light harvesting, and dual-ROS generation into a single platform for efficient photocatalysis in aqueous media.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
“Dual-Lock”-Controlled activatable nanotheranostics for chemiluminescence resonance energy transfer (CRET)-driven enhanced photoimmunotherapy
Photoimmunotherapy is a promising therapeutic modality which utilizes phototherapy to trigger immune responses for cancer therapy. However, the requirement of light to trigger the therapeutic procedure greatly suppress its efficacy...
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
“Dual-Lock”-Controlled activatable nanotheranostics for chemiluminescence resonance energy transfer (CRET)-driven enhanced photoimmunotherapy
Photoimmunotherapy is a promising therapeutic modality which utilizes phototherapy to trigger immune responses for cancer therapy. However, the requirement of light to trigger the therapeutic procedure greatly suppress its efficacy...
- 24 October 2024
- Published by Elsevier in Biomaterials
- Vol. 315, 122918
Bovine serum albumin framed activatable NIR AIE photosensitizer for targeted tumor therapy
- 24 October 2024
- Published by Elsevier in Biomaterials
- Vol. 315, 122918
Bovine serum albumin framed activatable NIR AIE photosensitizer for targeted tumor therapy
- Open Access
- 7 July 2024
- Published by Wiley in Advanced Science
- Vol. 11 (34) , e2404886
Metal‐Coordinated NIR‐II Nanoadjuvants with Nanobody Conjugation for Potentiating Immunotherapy by Tumor Metabolism Reprogramming
Immune checkpoint blockade (ICB) immunotherapy remains hampered by insufficient immunogenicity and a high‐lactate immunosuppressive tumor microenvironment (TME). Herein, a nanobody‐engineered NIR‐II nanoadjuvant with targeting metabolic reprogramming capability is constructed for potentiating NIR‐II photothermal‐ferroptosis immunotherapy. Specifically, the nanoadjuvant (2DG@FS‐Nb) is prepared by metallic iron ion‐mediated coordination self‐assembly of D‐A‐D type NIR‐II molecules and loading of glycolysis inhibitor, 2‐deoxy‐D‐glucose (2DG), followed by modification with aPD‐L1 nanobody (Nb), which can effectively target the immunosuppressive TME and trigger in situ immune checkpoint blockade. The nanoadjuvants responsively release therapeutic components in the acidic TME, enabling the precise tumor location by NIR‐II fluorescence/photoacoustic imaging while initiating NIR‐II photothermal‐ferroptosis therapy. The remarkable NIR‐II photothermal efficiency and elevated glutathione (GSH) depletion further sensitize ferroptosis to induce severe lipid peroxidation, provoking robust immunogenic cell death (ICD) to trigger anti‐tumor immune response. Importantly, the released 2DG markedly inhibits lactate generation through glycolysis obstruction. Decreased lactate efflux remodels the immunosuppressive TME by suppressing M2 macrophage proliferation and downregulating regulatory T cell levels. This work provides a new paradigm for the integration of NIR‐II phototheranostics and lactate metabolism regulation into a single nanoplatform for amplified anti‐tumor immunotherapy combined with ICB therapy.
- 7 July 2024
- Published by Wiley in Advanced Science
- Vol. 11 (34) , e2404886
Open AccessMetal‐Coordinated NIR‐II Nanoadjuvants with Nanobody Conjugation for Potentiating Immunotherapy by Tumor Metabolism Reprogramming
Immune checkpoint blockade (ICB) immunotherapy remains hampered by insufficient immunogenicity and a high‐lactate immunosuppressive tumor microenvironment (TME). Herein, a nanobody‐engineered NIR‐II nanoadjuvant with targeting metabolic reprogramming capability is constructed for potentiating NIR‐II photothermal‐ferroptosis immunotherapy. Specifically, the nanoadjuvant (2DG@FS‐Nb) is prepared by metallic iron ion‐mediated coordination self‐assembly of D‐A‐D type NIR‐II molecules and loading of glycolysis inhibitor, 2‐deoxy‐D‐glucose (2DG), followed by modification with aPD‐L1 nanobody (Nb), which can effectively target the immunosuppressive TME and trigger in situ immune checkpoint blockade. The nanoadjuvants responsively release therapeutic components in the acidic TME, enabling the precise tumor location by NIR‐II fluorescence/photoacoustic imaging while initiating NIR‐II photothermal‐ferroptosis therapy. The remarkable NIR‐II photothermal efficiency and elevated glutathione (GSH) depletion further sensitize ferroptosis to induce severe lipid peroxidation, provoking robust immunogenic cell death (ICD) to trigger anti‐tumor immune response. Importantly, the released 2DG markedly inhibits lactate generation through glycolysis obstruction. Decreased lactate efflux remodels the immunosuppressive TME by suppressing M2 macrophage proliferation and downregulating regulatory T cell levels. This work provides a new paradigm for the integration of NIR‐II phototheranostics and lactate metabolism regulation into a single nanoplatform for amplified anti‐tumor immunotherapy combined with ICB therapy.
- 6 July 2024
- Published by Elsevier in Journal of Materials Science & Technology
- Vol. 213, 196-212
Near-infrared-II triggered inorganic photodynamic nanomedicines for deep-tissue therapy
- 6 July 2024
- Published by Elsevier in Journal of Materials Science & Technology
- Vol. 213, 196-212
Near-infrared-II triggered inorganic photodynamic nanomedicines for deep-tissue therapy
- Open Access
- 4 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (30) , 12086-12097
Confined semiconducting polymers with boosted NIR light-triggered H 2 O 2 production for hypoxia-tolerant persistent photodynamic therapy
A mesoporous silica encapsulated semiconducting polymer with long-lived excited states and enhanced H 2 O 2 photo-production ability was combined with ferrous ions for hypoxia-tolerant persistent phototheranostics.
- 4 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (30) , 12086-12097
Open AccessConfined semiconducting polymers with boosted NIR light-triggered H 2 O 2 production for hypoxia-tolerant persistent photodynamic therapy
A mesoporous silica encapsulated semiconducting polymer with long-lived excited states and enhanced H 2 O 2 photo-production ability was combined with ferrous ions for hypoxia-tolerant persistent phototheranostics.
- 18 April 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (40) , 5322-5325
An NIR-II-emitting type-I photosensitizer for efficient hypoxic tumor phototheranostics
An NIR-II-emitting type-I photosensitizer with a strong push–pull effect and good planar π-conjugated structure was synthesized for efficient hypoxic tumor phototheranostics.
- 18 April 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (40) , 5322-5325
An NIR-II-emitting type-I photosensitizer for efficient hypoxic tumor phototheranostics
An NIR-II-emitting type-I photosensitizer with a strong push–pull effect and good planar π-conjugated structure was synthesized for efficient hypoxic tumor phototheranostics.
- 13 November 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (51) , e2305287
“Ice and Fire” Supramolecular Cell‐Conjugation Drug Delivery Platform for Deep Tumor Ablation and Boosted Antitumor Immunity
Cancer recurrence and metastasis are two major challenges in the current clinical therapy. In this work, a novel diketopyrrolopyrrole‐based photothermal reagent (DCN) with unique J‐aggregation‐induced redshift is synthesized to achieve efficient tumor thermal ablation under safe power (0.33 W cm−2). Meanwhile, S‐nitroso‐N‐acetylpenicillamine (SNAP) is co‐loaded with near‐infrared‐absorbing DCN in amphiphilic polymers to realize heat‐induced massive release of nitric oxide (NO), which can form oxidant peroxynitrite (ONOO−) to active matrix metalloproteinases (MMPs), thereby degrading the compact tumor extracellular matrix to improve the ablation depth and infiltration of immune cells. Through a facile supramolecular assembly method, the DCN/SNAP nanoparticles are anchored to liquid‐nitrogen‐frozen cancer cells, achieving enhanced antitumor immune responses and effective inhibition of distant tumors and pulmonary metastases after only one treatment. The safety and effectiveness of this supramolecular cell‐conjugation platform are verified by 2D/3D cellular experiments and bilateral tumor model, confirming the thermal‐ablation–gas‐permeation–antigen‐presentation therapeutic mode has promising anticancer prospects.
- 13 November 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (51) , e2305287
“Ice and Fire” Supramolecular Cell‐Conjugation Drug Delivery Platform for Deep Tumor Ablation and Boosted Antitumor Immunity
Cancer recurrence and metastasis are two major challenges in the current clinical therapy. In this work, a novel diketopyrrolopyrrole‐based photothermal reagent (DCN) with unique J‐aggregation‐induced redshift is synthesized to achieve efficient tumor thermal ablation under safe power (0.33 W cm−2). Meanwhile, S‐nitroso‐N‐acetylpenicillamine (SNAP) is co‐loaded with near‐infrared‐absorbing DCN in amphiphilic polymers to realize heat‐induced massive release of nitric oxide (NO), which can form oxidant peroxynitrite (ONOO−) to active matrix metalloproteinases (MMPs), thereby degrading the compact tumor extracellular matrix to improve the ablation depth and infiltration of immune cells. Through a facile supramolecular assembly method, the DCN/SNAP nanoparticles are anchored to liquid‐nitrogen‐frozen cancer cells, achieving enhanced antitumor immune responses and effective inhibition of distant tumors and pulmonary metastases after only one treatment. The safety and effectiveness of this supramolecular cell‐conjugation platform are verified by 2D/3D cellular experiments and bilateral tumor model, confirming the thermal‐ablation–gas‐permeation–antigen‐presentation therapeutic mode has promising anticancer prospects.